DLL3 . NUEVOS AVANCES , EXPECTATIVAS Y NUEVOS TRATAMIENTOS PARA EL SMALL CELL LUNG CANCER EN RECAÍDA . El Receptor DLL3 está Ampliamente Presente en el SAMLL CELL LUNG CANCER , lo Que lo Convierte en un Objetivo Potencial Para la INMUNOTERAPIA .

JANUARY 2025 

SMALL CELL LUNG CANCER ( SCLC ) Is An Aggressive Form Of Neuroendocrine Neoplasm Known For Its Striking Initial  Response To Treatment, Followed By Fast RELAPSE And REFRACTORINESS In Response To Additional Lines Of THERAPY . 

New Advances in IMMUNOTHERAPY Are Paving The Way For More Effective Treatment Strategies And Have Promising Results With Early Clinical Trial Data .

 While SCLC Rarely Harbors Actionable Mutations, The Receptor DLL3 IS Extensively Present in SCLC, Making It a Potential Target For IMMUNOTHERAPY .

 Three Emerging Therapeutic Options Include Bispecific T Cell Engagers Targeting DLL3, Chimeric Antigen Receptor T Cells ( CAR-T Cells ), And Antibody–Drug  Conjugates .

Several PHASE II And PHASE III Clinical Trials For Bispecific T Cell Engagers Show Promise . 

Additionally, The Furst CAR-T Cell Trials in Humans For SCLC Are Currently Underway . ...

********************

***************

********

EN MARCHA ALREDEDOR DE 30 ENSAYOS CLÍNICOS DIRIGIDOS A DLL3 SCLC A NIVEL MUNDIAL ... AQUI VAN ALGUNOS DE ELLOS :

• TARLATAMAB ( IMDELLTRA ) LLEVA 14 ENSAYOS CLINICOS  DLL3 EN FASE I, II. III  .
• TARLATAMAB COMBINADO Con PEMBROLIZUMAB 
• TARLATAMAB COMBINADO CON ETOPÓSIDO/ CARBOPLATIN 
• TARLATAMAB FRENTE A LURBINECTEDIN 
• MK-6070 COMBINADO con ATEZOLIZUMAB 
• PT217 COMBINADO CON ATEZOLIZUMAB 
• LB2102-1001
• Drug: 89Zr-DFO
• Drug: SC16.56
• BHP01-01
• SNC115-DLL3 CART-101
• BI 764532
• Obrixtamig
•  Ezabenlimab
• AMG 119

...